MSI-H/dMMR + POLE mutation
|
Gastric Cancer
|
MSI-H/dMMR + POLE mutation
|
Gastric Cancer
|
dostarlimab Sensitive: C3 – Early Trials
|
dostarlimab Sensitive: C3 – Early Trials
|
MSI-H/dMMR + POLE mutation
|
CRC
|
MSI-H/dMMR + POLE mutation
|
CRC
|
dostarlimab Sensitive: C3 – Early Trials
|
dostarlimab Sensitive: C3 – Early Trials
|
MSI-H/dMMR + POLE mutation
|
NSCLC
|
MSI-H/dMMR + POLE mutation
|
NSCLC
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|